Heba Farouk SALEM, Mohamed Nabil Abd El HAMİD, Amira Shaban AHMED, Rania M. SARHANL

The Effect of Hydroxychloroquine Treatment on Blood Sugar Level, Serum Lipid Profile and the Retina in Systemic Lupus Erythematosus Patients

The aim of this study was to evaluate the effect of hydroxychloroquine (HCQ) on blood sugar level, lipid profile and retina in newly diagnosed systemic lupus erythromatosus (SLE) patients. Fifty newly diagnosed SLE patients were collected from Immunology and Rheumatology outpatient clinics in Beni Suef University hospital. All patient's questionnaire included name, age, sex, smoking status, the date of the diagnosis, drugs taken during the follow up period and present history of other diseases. Only HCQ was prescribed to the patients within one year follow-up. They were with a mean (SD, range) age 30 (7.07, 25, 35) years old. Their total lipid profile which included total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL) and fasting blood sugar (FBG) and postprandial blood glucose levels (PPBG) were analyzed in MASTER LAB in Beni suef before and after 6 months from the using of HCQ as well as our patients were converted to Ophthalmology Department in Beni Suef University hospital before and at the end of six months of HCQ therapy to undergo to complete eye examinations. The mean (SD) of TC, TG, LDL, FBG and PPBG were significantly decreased after HCQ than before using it while HDL was increased at p

PDF

___

Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. Immunol. 2006; 176(12):7143 —7.

Bertsias G, Gordon C, Boumpas D. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future—the EULAR recommendations for the management of SLE and the use of end—points in clinical trials. Lupus. 2008;17(5):437—42.

Dörner T, Therapy: hydroxychloroquine in SLE: old drug, new perspectives. Nature Reviews Rheumatology. 2010;6(1):10-1.

Solomon DH, Garg R, Lu B, Todd DJ, Mercer E, Norton T, Massarotti E. The effect of hydroxychloroquine on insulin sensitivity and lipid parameters in non-diabetic patients with rheumatoid arthritis: randomized blinded cross-over trial. Arthritis Care Res. 2014;66(8):l246—51.

Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol. 2012;130(4):461—9.

Cairoli E, Rebella M, Danese N, Garra V, Borba EF. Hydroxychloroquine reduces low—density lipoprotein cholesterol levels in systemic lupus erythematosus: longitudinal evaluation of the lipid—lowering effect. Lupus. 2012;21(1 1):1 178—82.

Kim JS, Oh JS, Chang EA, Bae SY, Nam DH, Lee CH, Yang JH, Lee CK, Lee WJ, Kim HC, Klein TA, Lim CS, Kim YK. Alteration of platelet counts and lipid profiles after treatment of acute Plasmodium vivaX Acta Tropica. 2008;106(1):39—43.

Nikpour M, Gladman DD, lbanez D, Harvey PJ, Urowitz MB. Research article Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: longitudinal cohort study. Arthritis Res Ther. 2010;12(3):R125.

Kang L, Mikuls TR, O’Dell JR. Reminder of important clinical lesson: Hydroxychloroquine: diabetic drug in disguise? BMJ Case Rep. 2009;20092bcr0820080654.

Wasko, MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward MM., Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298(2):187—93.

Bili A, Sartorius JA, Kirchner HL, Morris SJ, Ledwich LJ, Antohe JL, Dancea S, Newman ED, Wasko MC. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. Clin Rheumatol. 2011;17(3):115-20.

Mercer E, Rekedal L, Garg R, Lu B, Massarotti EM, Solomon DH. Hydroxychloroquine improves insulin sensitivity in obese non—diabetic individuals. Arthritis Res Ther. 2012;14(3):R135.

Penn S.K, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, Manzi S, Wasko MC. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. Rheumatol. 2010;37(6):l 136-42.

Andrade RM, Alarcon GS. Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatol. 2006;12225 —33.

Sivaraj R, Durrani OM, Denniston AK, Murray Pl, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology. 2007;46(l2):l757—62.

Browning DJ. Toxicology of Hydroxychloroquine and Chloroquine and the Pathology of the Retinopathy They Cause. Hydroxychloroquine and Chloroquine Retinopathy. 2014;Springer:65—83.

Browning DJ. Risk Factors for Hydroxychloroquine and Chloroquine Retinopathy. Hydroxychloroquine and Chloroquine Retinopathy. 2014;Springer:l33-54.

Ochsendorf FR. Use of antimalarials in dermatology. JDDG. 2010;8(10): 829—845.

Kaufmann AM, Krise JP. Lysosomal sequestration of amine-containing drugs: Analysis and therapeutic implications. Pharm Sci. 2007;96(4):729-46.

Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dennatology. Dermatol Ther. 2007;20(4):l60—74.

Wozniacka A, Carter A, McCauliffe D. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus. 2002;ll(2):7l—81.

Sarkissian T. Beyene J, Feldman B, McCrindle B, Silverman ED. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum. 2007;56(2):63 1—8.

Soep JB, Mietus—Snyder M, Malloy MJ Witztum L, von Scheven E. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum. 2004;51(3):451—7.

Borba EF, Carvalho JF, Bonfa E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev lmmunol. 2006;l3(2—4):203—8.

Migkos MP, Markatseli TE, Iliou C, Voulgari PV, Drosos AA. Effect of Hydroxychloroquine on the Lipid Profile of Patients with Sjögren Syndrome. Rheumatol. 2014;4l(5):902—8.

Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat ReV Rheumatol. 2012;8(9):522—33.

Antohe JL, Bili A, Sartorius JA, Kirchner HL, Morris SJ, Dancea S, Wasko MC. Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti—tumor necrosis factor therapy. Arthritis Care Res. 2012;64(2):215—21.

Bessant R, Hingorani A, Patel L, MacGregor A, lsenberg DA, Rahman A. Risk of coronary heart disease and stroke in large British cohort of patients with systemic lupus erythematosus. Rheumatology. 2004;43(7):924—9.

Rekedal LR, Elena Massarotti BA, Garg R, Bhatia R, Gleeson T, Lu B, Solomon DH. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum. 2010;62(l2):3569—73.

Winter EM, Schrander—van der Meer A, Eustatia—Rutten C, Janssen M. Hydroxychloroquine as glucose lowering drug. BMJ Case Reports. 2011;2011:bcr0620114393.

Fletcher B, Lamendola C. Insulin resistance syndrome. Cardiovasc Nurs. 2004;l9(5):339—45.

Rodriguez—Caruncho C, Marsol IB. Antimalarials in dermatology: mechanism of action, indications, and side effects. Actas Dermosifiliogr. 2014;105(3):243—52.

Chen YM, Lin CH, Lan TH, Chen HH, Chang SN, Chen YH, Wang JS, Hung WT, Lan JL, Chen DY. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in dose—dependent manner: population-based cohort study. Rheum. 2015;54(7):1244—9.

Zeng Y, Zeng FQ, Dai L, Yang C, Lin BZ, Zheng DH, Liu D, Yan L, Ren M. Cheng H., Characteristics and risk factors for hyperglycemia in Chinese female patients with systemic lupus erythematosus. Lupus. 2010;l9(l l):l344—50.

Posadas-Romero C, Torres—Tamayo M, Zamora—Gonzalez J, Aguilar—Herrera BE, Posadas—Sanchez R, Cardoso—Saldafia G, Ladrén de Guevara G, Solis—Vallejo E, El Hafidi M. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients With systemic lupus erythematosus. Arthritis Rheum. 2004;50(l):160—5.

Bruce IN, Urowitz MB, Gladman DD, Ibafiez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum. 2003;48(l l):3159—67.

Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients With rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62(6):775—84.

Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. American Academy of Ophthalmology, Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 201 l;l 18(2):415—22.

Ostanek L, Modrzejewska M, Bobrowska—Snarska D, Brzosko M, [Ocular manifestations in patients With systemic lupus erythematosus and antiphospholipid syndrome]. Polskie Archiwum Medycyny Wewnetrznej. 2007;117:18—23.

40. Aliö JL, Pifıero DP, Tomas J, Plaza AB. Vector analysis of astigmatic changes after cataract surgery With implantation of new toric multifoc al intraocular lens. Cataract Refract Surg. 2011;37(7):1217—29.

41. Li H, Leung CK, Wong L, Cheung CY, Pang CP, Weinreb RN, Lam DS. Comparative study of central corneal thickness measurement With slit—lamp optical coherence tomography and Visante optical coherence tomography. Ophthalmology. 2008; 15(5):796—801

42. Pandhi D, Singal A, Rohtagi J. Eyelid involvement in disseminated chronic cutaneous lupus erythematosus. Indian Dermatol Venereol Leprol. 2006;72(5):370—2.